These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

151 related articles for article (PubMed ID: 27306575)

  • 1. Utilising a hybrid anti-Xa calibration assay in unfractionated heparin (UFH) monitoring: validation of assay and its correlation with activated partial thromboplastin time (aPTT).
    Lukito P; Collecutt M; Dauer R; Morgan S; Tran H
    Pathology; 2016 Aug; 48(5):501-3. PubMed ID: 27306575
    [No Abstract]   [Full Text] [Related]  

  • 2. A comparative trial of anti-factor Xa levels versus the activated partial thromboplastin time for heparin monitoring.
    Vandiver JW; Vondracek TG
    Hosp Pract (1995); 2013 Apr; 41(2):16-24. PubMed ID: 23545756
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Activated partial thromboplastin time versus antifactor Xa heparin assay in monitoring unfractionated heparin by continuous intravenous infusion.
    Guervil DJ; Rosenberg AF; Winterstein AG; Harris NS; Johns TE; Zumberg MS
    Ann Pharmacother; 2011 Jul; 45(7-8):861-8. PubMed ID: 21712506
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The PiCT
    Brisset AC; Ferrández A; Krause M; Rathbun S; Marlar R; Korte W
    J Thromb Haemost; 2016 Nov; 14(11):2187-2193. PubMed ID: 27582411
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Antifactor Xa levels versus activated partial thromboplastin time for monitoring unfractionated heparin.
    Vandiver JW; Vondracek TG
    Pharmacotherapy; 2012 Jun; 32(6):546-58. PubMed ID: 22531940
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Activated partial thromboplastin time and anti-xa measurements in heparin monitoring: biochemical basis for discordance.
    Takemoto CM; Streiff MB; Shermock KM; Kraus PS; Chen J; Jani J; Kickler T
    Am J Clin Pathol; 2013 Apr; 139(4):450-6. PubMed ID: 23525615
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Antifactor Xa levels vs. activated partial thromboplastin time for monitoring unfractionated heparin. A pilot study.
    Samuel S; Allison TA; Sharaf S; Yau G; Ranjbar G; Mckaig N; Nguyen A; Escobar M; Choi HA
    J Clin Pharm Ther; 2016 Oct; 41(5):499-502. PubMed ID: 27381025
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The use of anti-Xa assay to monitor intravenous unfractionated heparin therapy.
    Rosenberg AF; Zumberg M; Taylor L; LeClaire A; Harris N
    J Pharm Pract; 2010 Jun; 23(3):210-6. PubMed ID: 21507816
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Interlaboratory variation in heparin monitoring: Lessons from the Quality Management Program of Ontario coagulation surveys.
    Cuker A; Raby A; Moffat KA; Flynn G; Crowther MA
    Thromb Haemost; 2010 Oct; 104(4):837-44. PubMed ID: 20664895
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Theophylline adenosine dipyridamole (CTAD) and citrate evaluation to survey unfractionated heparin treatment: a delayed centrifugation validation for anti-Xa measurement?].
    Billoir P; Clavier T; Guilbert A; Barbay V; Chrétien MH; Fresel M; Abriou C; Girault C; Le Cam Duchez V
    Ann Biol Clin (Paris); 2020 Feb; 78(1):27-34. PubMed ID: 32108577
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Anti-factor Xa (anti-Xa) assay.
    Newall F
    Methods Mol Biol; 2013; 992():265-72. PubMed ID: 23546719
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A comparison of red blood cell transfusion utilization between anti-activated factor X and activated partial thromboplastin monitoring in patients receiving unfractionated heparin.
    Belk KW; Laposata M; Craver C
    J Thromb Haemost; 2016 Nov; 14(11):2148-2157. PubMed ID: 27543785
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Performance Assessment of a Multifaceted Unfractionated Heparin Dosing Protocol in Adult Patients on Extracorporeal Membrane Oxygenator.
    Al-Jazairi A; Raslan S; Al-Mehizia R; Dalaty HA; De Vol EB; Saad E; Alanazi M; Owaidah T
    Ann Pharmacother; 2021 May; 55(5):592-604. PubMed ID: 32959678
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Comparison of unfractionated heparin protocols using antifactor Xa monitoring or activated partial thrombin time monitoring.
    Frugé KS; Lee YR
    Am J Health Syst Pharm; 2015 Sep; 72(17 Suppl 2):S90-7. PubMed ID: 26272899
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Monitoring heparin anticoagulation in the acute phase response.
    Uprichard J; Manning RA; Laffan MA
    Br J Haematol; 2010 May; 149(4):613-9. PubMed ID: 20230412
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Establishing a new target range for unfractionated heparin for acute coronary syndromes.
    Lee MS; Menon V; Schappert J; Wilentz JR; Singh V; Hochman JS
    J Thromb Thrombolysis; 2004 Apr; 17(2):121-6. PubMed ID: 15306747
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Clinical use of unfractionated heparin therapy in children: time for change?
    Newall F; Ignjatovic V; Johnston L; Summerhayes R; Lane G; Cranswick N; Monagle P
    Br J Haematol; 2010 Sep; 150(6):674-8. PubMed ID: 20629660
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Evaluation of Antifactor-Xa Heparin Assay and Activated Partial Thromboplastin Time Values in Patients on Therapeutic Continuous Infusion Unfractionated Heparin Therapy.
    McLaughlin K; Rimsans J; Sylvester KW; Fanikos J; Dorfman DM; Senna P; Connors JM; Goldhaber SZ
    Clin Appl Thromb Hemost; 2019; 25():1076029619876030. PubMed ID: 31530176
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Anti-factor Xa assay is a superior correlate of heparin dose than activated partial thromboplastin time or activated clotting time in pediatric extracorporeal membrane oxygenation*.
    Liveris A; Bello RA; Friedmann P; Duffy MA; Manwani D; Killinger JS; Rodriquez D; Weinstein S
    Pediatr Crit Care Med; 2014 Feb; 15(2):e72-9. PubMed ID: 24335992
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Activated Partial Thromboplastin Time Monitoring of Unfractionated Heparin Therapy: Issues and Recommendations.
    Marlar RA; Clement B; Gausman J
    Semin Thromb Hemost; 2017 Apr; 43(3):253-260. PubMed ID: 27272964
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.